Partial Oral Therapy for Pediatric Infective Endocarditis
Abstract
Derry R. McDonald, PharmD; MB 5.420, PO Box 5371, 4800 Sand Point Way NE, Seattle, WA 98105; [email protected]
No funding sources were applied to this research.
The authors declare they have no financial or personal conflicts of interest to disclose.
The 2015 American Heart Association and American College of Cardiology adult and pediatric infective endocarditis (IE) guidelines recommend parenteral antibiotics as empiric and definitive therapy while the 2023 European Society for Cardiology (ESC) guidelines endorsed transition to oral antibiotic therapy for some adults with IE. Apart from the ESC guidelines and retrospective case reviews, evidence for enteral therapy of pediatric infective endocarditis is lacking. We sought to apply findings from the adult trials to the pediatric population and evaluate clinical outcomes for pediatric infective endocarditis patients who transitioned to enteral antibiotic therapy.
The Antimicrobial Stewardship Program (ASP), in collaboration with the divisions of Infectious Diseases and Cardiology, developed and implemented a hospital protocol to facilitate the transition from IV to enteral antibiotics for endocarditis. In this single-center quality assessment and case series, we conducted a retrospective chart review of endocarditis inpatient admissions between December 1, 2023 and June 30, 2024 utilizing the hospital electronic health care record. Patients were identified using ICD-10 diagnoses and corroborated against an…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.